BOTOX is more like $1.3 b. Always been fragile. BOTOX is starting to get competition in Eurozone from RELOXIN.
We thought this was just another Palomar technology until we looked at it closer. The combo makes this a different animal altogether. No wonder JNJ left Palomar last year.
We didn't know anything about J Plasma. We found you guys from this on Goog. Then we saw your 510K and that got attention.
Bovie Medical Announces Joint Venture to Manufacture and Market J-Plasma; A New Surgical Plasma Technology Device Business Wire, March 2, 2000 12Next Business Editors, Health/Medical Writers
MELVILLE, N.Y.--(BUSINESS WIRE)--March 2, 2000
Bovie Medical Corporation (the "Company" or "Bovie") (OTC Bulletin Board Symbol:BOVI), a manufacturer and marketer of electrosurgical products today announced that it entered into a co-equal joint venture with a European technology development company to manufacture and market worldwide, J-Plasma, a new-patented plasma technology that could significantly improve current surgical procedures. Although J-Plasma will initially be utilized in plastic surgery and dermatology, management anticipates possible uses in many types of surgery, including cancer, neuro, cardiovascular and gynecologic and endoscopic procedures.
Bovie Medical Corporation Announces Submission of 510(k) Application for Its... Acoustic Monitoring of Plasma Arcs in Direct Current Electric Arc Furnaces Time-Course of Tissue Factor Plasma Level in Patients with Acute Coronary... Plasma Prohepcidin as a Negative Acute Phase Reactant after Large Cardiac... Regionally-Selective Cell Colonization of Micropatterned Surfaces Prepared by... The device produces a stable thin focused beam of ionized gas that can be controlled in a wide range of temperatures and intensities providing the surgeon with precision, minimal invasiveness and an absence of conductive currents during surgery.
The joint venture is developing its first commercial prototypes for uses in dermatology and plastic surgery and upon their completion; Bovie intends to file the appropriate applications with the Food and Drug Administration (FDA) for these uses. Applications in other areas of surgery require further testing and will be subject to FDA approvals.
Bovie's management believes J-Plasma is potentially an important advance to traditional surgical operations and will be cost effective and complementary to Bovie's electrosurgical product line.